To generate and present survey results on important issues relevant to treatment and follow-up of localized and locally advanced, high-risk prostate cancer (PCa) focusing on developing countries.
A panel of 99 PCa experts developed more than 300 survey questions of which 67 questions concern the main areas of interest of this article: treatment and follow-up of localized and locally advanced, high-risk PCa in developing countries. A larger panel of 99 international multidisciplinary cancer experts voted on these questions to create the recommendations for treatment and follow-up of localized and locally advanced, high-risk PCa in areas of limited resources discussed in this article.
The panel voted publicly but anonymously on the predefined questions. Each question was deemed consensus if 75% or more of the full panel had selected a particular answer. These answers are based on panelist opinion and not on a literature review or meta-analysis. For questions that refer to an area of limited resources, the recommendations considered cost-effectiveness as well as the possible therapies with easier and greater access. Each question had five to seven relevant answers including two nonanswers. Results were tabulated in real time.
The voting results and recommendations presented in this article can guide physicians managing localized and locally advanced, high-risk PCa in areas of limited resources. Individual clinical decision making should be supported by available data; however, as guidelines for treatment of localized and locally advanced, high-risk PCa in developing countries have not been defined, this article will serve as a point of reference when confronted with this disease.
JCO global oncology. 2021 Apr [Epub]
Raja Khauli, Robson Ferrigno, Gustavo Guimarães, Muhammad Bulbulan, Pedro Luiz Serrano Uson Junior, Bernardo Salvajoli, Daniel Moore Freitas Palhares, Douglas Racy, Erlon Gil, Fernando Freire de Arruda, Gustavo Caserta Lemos, Gustavo Franco Carvalhal, Icaro Thiago de Carvalho, Igor Austin Fernandes Martins, Ivan Frederico Pinto Gimpel, João Victor Salvajoli, José Luis Chambo, José Pontes, Leopoldo Alves Ribeiro Filho, Lucas Nogueira, Marcelo Roberto Pereira Freitas, Marcelo Wroclawski, Marco Antonio Arap, Marcus Vinicius Sadi, Rafael Coelho, Rafael Gadia, Rodrigo Antonio Ledezma Roja, Rodrigo de Moraes Hanriot, Ronaldo Baroni, Stenio Zequi, William Carlos Nahas, Wladimir Alfer, Fernando Cotait Maluf
Naef K. Basile Cancer Institute, Beirut, Lebanon., Hospital BP, São Paulo, Brazil., American University of Beirut, Beirut, Lebanon., Hospital Israelita Albert Einstein, São Paulo, Brazil., Instituto do Câncer de São Paulo, São Paulo, Brazil., Hospital Sírio Libanês, São Paulo, Brazil., Hospital Moinho de Ventos, Porto Alegre, Brazil., Clínica Santa María, Providencia, Chile., Universidade Federal de Minas Gerais, Belo Horizonte, Brazil., Centro de Pesquisas Oncológicas de Santa Catarina, Santa Catarina, Brazil., Universidad de Chile, Santiago, Chile., Hospital Alemão Oswaldo Cruz, São Paulo, Brazil., Hospital do Câncer AC Camargo, São Paulo, Brazil.